Abstract：
BACKGROUND: Ankylosing spondylitis (AS) is a chronic condition that requires lifelong treatment and results in a serious disease burden. Health state utility values (HSUVs) are a valuable tool for quantifying this burden and conducting cost-utility analysis.
OBJECTIVE: We conducted a systematic review and meta-analysis to obtain estimates of HSUVs in patients with AS, explored potential sources of heterogeneity, and compared pooled patient HSUVs with population norms.
METHODS: We searched PubMed, Embase, Web of science, Cochrane database and Scopus until July, 2023 to obtain eligible studies. The methodological quality of the included studies was assessed using the ROBINS-I checklist.
RESULTS: Forty-two publications involving 11,354 participants were included in this systematic review. The most commonly used instrument is the EQ-5D (38 studies). The estimated HSUVs for patients with AS from all available studies was pooled as 0.62 (95% CI 0.59 to 0.65). The pooled mean utility estimates from the random effects meta-analysis for SF-6D, EQ-5D-3L, EQ-5D-5L, and HUI3 were 0.65 (95% CI 0.62,0.68), 0.63 (95% CI 0.59,0.66), 0.60 (95% CI 0.42,0.79), and 0.48 (95% CI 0.43,0.53), respectively. For the EQ-5D-3L we conducted stratified meta-analyses and meta-regression based on key subgroups. The pooled estimates of EQ-5D-3L were lower for patients published before 2010, with high disease activity, long duration of disease, and in developed countries.
CONCLUSIONS: Pooled estimates of HSUVs for people with AS were substantially lower than population norms. These estimates provide robust evidence that can inform the economic evaluation of new therapies for individuals with AS.
OBJECTIVE: We conducted a systematic review and meta-analysis to obtain estimates of HSUVs in patients with AS, explored potential sources of heterogeneity, and compared pooled patient HSUVs with population norms.
METHODS: We searched PubMed, Embase, Web of science, Cochrane database and Scopus until July, 2023 to obtain eligible studies. The methodological quality of the included studies was assessed using the ROBINS-I checklist.
RESULTS: Forty-two publications involving 11,354 participants were included in this systematic review. The most commonly used instrument is the EQ-5D (38 studies). The estimated HSUVs for patients with AS from all available studies was pooled as 0.62 (95% CI 0.59 to 0.65). The pooled mean utility estimates from the random effects meta-analysis for SF-6D, EQ-5D-3L, EQ-5D-5L, and HUI3 were 0.65 (95% CI 0.62,0.68), 0.63 (95% CI 0.59,0.66), 0.60 (95% CI 0.42,0.79), and 0.48 (95% CI 0.43,0.53), respectively. For the EQ-5D-3L we conducted stratified meta-analyses and meta-regression based on key subgroups. The pooled estimates of EQ-5D-3L were lower for patients published before 2010, with high disease activity, long duration of disease, and in developed countries.
CONCLUSIONS: Pooled estimates of HSUVs for people with AS were substantially lower than population norms. These estimates provide robust evidence that can inform the economic evaluation of new therapies for individuals with AS.
摘要：
背景：强直性脊柱炎（AS）是一种慢性疾病，需要终身治疗，并导致严重的疾病负担。健康状态效用值（HSUV）是量化这种负担并进行成本效用分析的宝贵工具。
目的：我们进行了系统回顾和荟萃分析，以获得AS患者的HSUV估计值，探索异质性的潜在来源，并将合并的患者HSUV与人群规范进行了比较。
方法：我们搜索了PubMed，Embase,WebofScience,Cochrane数据库和Scopus直到7月，2023年获得符合条件的研究。使用ROBINS-I检查表评估纳入研究的方法学质量。
结果：本系统综述包括42篇出版物，涉及11,354名参与者。最常用的仪器是EQ-5D（38项研究）。来自所有可用研究的AS患者的估计HSUV汇总为0.62（95％CI0.59至0.65）。来自SF-6D随机效应荟萃分析的合并平均效用估计，EQ-5D-3L,EQ-5D-5L,HUI3为0.65（95%CI0.62,0.68），0.63（95%CI0.59,0.66），0.60（95%CI0.42,0.79），和0.48（95%CI0.43,0.53），分别。对于EQ-5D-3L，我们基于关键亚组进行了分层meta分析和meta回归。2010年之前发表的EQ-5D-3L的合并估计值较低，疾病活动度高，疾病持续时间长，在发达国家。
结论：AS患者的HSUV汇总估计值大大低于人群常值。这些估计提供了有力的证据，可以为AS患者的新疗法的经济学评估提供依据。
目的：我们进行了系统回顾和荟萃分析，以获得AS患者的HSUV估计值，探索异质性的潜在来源，并将合并的患者HSUV与人群规范进行了比较。
方法：我们搜索了PubMed，Embase,WebofScience,Cochrane数据库和Scopus直到7月，2023年获得符合条件的研究。使用ROBINS-I检查表评估纳入研究的方法学质量。
结果：本系统综述包括42篇出版物，涉及11,354名参与者。最常用的仪器是EQ-5D（38项研究）。来自所有可用研究的AS患者的估计HSUV汇总为0.62（95％CI0.59至0.65）。来自SF-6D随机效应荟萃分析的合并平均效用估计，EQ-5D-3L,EQ-5D-5L,HUI3为0.65（95%CI0.62,0.68），0.63（95%CI0.59,0.66），0.60（95%CI0.42,0.79），和0.48（95%CI0.43,0.53），分别。对于EQ-5D-3L，我们基于关键亚组进行了分层meta分析和meta回归。2010年之前发表的EQ-5D-3L的合并估计值较低，疾病活动度高，疾病持续时间长，在发达国家。
结论：AS患者的HSUV汇总估计值大大低于人群常值。这些估计提供了有力的证据，可以为AS患者的新疗法的经济学评估提供依据。
